Perioperative intravenous paracetamol as adjunctive treatment for postoperative pain relief after orthopaedic surgery involving lower limb bone fracture by Muda, Mohd Izwan Azmi
i 
 
PERIOPERATIVE INTRAVENOUS PARACETAMOL AS 
ADJUNCTIVE TREATMENT FOR POSTOPERATIVE PAIN 
RELIEF AFTER ORTHOPAEDIC SURGERY INVOLVING 
LOWER LIMB BONE FRACTURE 
 
By 
DR MOHD IZWAN AZMI BIN MUDA 
 
 
Dissertation Submitted in Partial Fulfilment of the 
Requirement for the Degree of Master of Medicine 
 (ANAESTHESIOLOGY) 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2016 
  
ii 
 
ACKNOWLEDGEMENT 
I would like to take the opportunity here to thank all who have helped me complete this 
study successfully 
First and foremost, I would like to express my gratitude and respect for my supervisor, 
Professor Dr. Nik Abdullah Nik Mohamad for his guidance and input. I would also like 
to thank my co-supervisor and Head of Department of Anaesthesiology, Hospital 
Universiti Sains Malaysia, Professor Dr. Shamsul Kamalrujan Hassan. Besides that, I 
would like to thank to Dato’ Dr. Aisai bin Abdul Rahman as my ministry of Health 
supervisor and Head Department of Anaesthesiology and Intensive Care, Hospital 
Sultanah Nur Zahirah. 
Besides that, I would also like to thank all lecturers in the Anaesthesiology and 
Intensive Care Department and Biostatistics and Research Methodology Unit of 
Universiti Sains Malaysia for their constant guidance and help throughout the research 
process. Their input and advice had been a great help to me. 
To my colleagues, friends, and supporting staff who have helped me directly and 
indirectly in this study, I express my deepest gratitude. 
Last but not least, to my dear wife and family for their support and understanding 
without which none of this is possible. 
 
  
iii 
 
TABLE OF CONTENTS 
           Page 
Title           i 
Acknowledgement         ii 
Table of Contents         iii 
List of Tables          vii 
List of Figures          viii 
Abstrak          x 
Abstract          xii 
Chapter 1   Introduction        1 
1.1 Introduction         1 
1.2 Objective of the Study       5 
Chapter 2 Review of Literatures       6 
2.1 Physiology of Pain        6 
 2.1.1 Pain Pathways        9 
 2.1.2 Modulation of Perception of Pain     12 
2.2 Concept of Multimodal Analgesia      14 
 2.2.1 Opioids        16 
iv 
 
 2.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)   17 
 2.2.3 Cox-2 Selective Inhibitor      19 
 2.2.4 NMDA Antagonists       21 
 2.2.5 Alpha-2 Agonist       22 
 2.2.6 Gabapentanoids       23 
 2.2.7 Local Anaesthetics       24 
2.3 Paracetamol         26 
 2.3.1 Introduction        26 
 2.3.2 Pharmacodynamics       28 
 2.3.3 Pharmacokinetics       30 
 2.3.4 Side Effects and Toxicity of Paracetamol    35 
 2.3.5 Clinical Studies of Intravenous Paracetamol in Postoperative 37
  Management 
 2.3.6 Clinical Studies of Intravenous Paracetamol in Orthopaedics  39
  Surgery 
 2.3.7 Comparative Studies of Intravenous Paracetamol with Others 41
  Analgesic 
Chapter 3 Methodology        42 
3.1 Study Design         42 
v 
 
3.2 Sample Size         43 
3.3 Inclusion and Exclusion Criteria      44 
3.4 Study Method         45 
3.5 Data Entry and Analysis       47 
Chapter 4 Results         48 
4.1 Demographic Data        48 
4.2 Pain Score and Cumulative Morphine Consumption    55 
 4.2.1 Resting Pain Score       55 
 4.2.2 Moving Pain Score       57 
 4.2.3 Cumulative Morphine Consumption     59 
4.3 Side Effects         61 
 4.3.1 Nausea        61 
 4.3.2 Vomiting        63 
 4.3.3 Dizziness        65 
 4.3.4 Others         67 
Chapter 5 Discussion        68 
5.1 Limitations of this Study       71 
Chapter 6 Summary and Conclusion      72 
vi 
 
Chapter 7  Recommendations       73 
References          74 
Appendices          82 
 Appendix A: Patient information sheet and consent in Malay  83 
 Appendix B: Patient information sheet and consent in English  89 
 Appendix C: Data Collection Form      94 
  
vii 
 
LIST OF TABLES 
Table 2.1 Major neurotransmitters mediating and modulating pain. 
Table 4.1 Patient Characteristics and Type and Duration of Operation 
Table 4.2 Mean resting pain score ± SD measured using visual analogue scale at 
the preoperative period, 30 minutes, 3 and 6 hours postoperatively 
Table 4.3 Mean moving pain score ± SD measured using visual analogue scale at 
the preoperative period, 30 minutes, 3 and 6 hours postoperatively 
Table 4.4 Mean cumulative morphine consumption ± SD at 30 minutes, 3 and 6 
hours postoperatively 
Table 4.5 Number and percentage of patients experiencing nausea at 30 minutes, 
3 and 6 hours postoperatively 
Table 4.6 Number and percentage of patients experiencing vomiting at 30 
minutes, 3 and 6 hours postoperatively 
Table 4.7 Number and percentage of patients experiencing dizziness at 30 
minutes, 3 and 6 hours postoperatively 
 
  
viii 
 
LIST OF FIGURES 
Figure 2.1 Pain pathways. 
Figure 2.2 The pain pathway and intervention that can modulate activity at each 
point 
Figure 2.3 Structure of Paracetamol 
Figure 4.1 CONSORT diagram 
Figure 4.2 Mean age of patients in intravenous paracetamol and placebo group 
Figure 4.3 Gender distributions in percentage in intravenous paracetamol and 
placebo group 
Figure 4.4 Distribution of patients between intravenous paracetamol and placebo 
group according to type of operation 
Figure 4.5 Mean duration of operation in intravenous paracetamol and placebo 
group 
Figure 4.6 Mean resting pain score measured using visual analogue scale at the 
preoperative period and ½, 3 and 6 hours postoperatively for intravenous 
paracetamol and placebo group. 
Figure 4.7 Mean moving pain score measured using visual analogue scale at the 
preoperative period and ½, 3 and 6 hours postoperatively for intravenous 
paracetamol and placebo group. 
ix 
 
Figure 4.8 Mean cumulative morphine consumption at ½, 3 and 6 hours 
postoperatively for intravenous paracetamol and placebo group. 
Figure 4.9 Comparison of percentage of patients experiencing nausea between 
intravenous paracetamol and placebo group at 1/2, 3 and 6 hours 
postoperatively 
Figure 4.10 Comparison of percentage of patients experiencing vomiting between 
intravenous paracetamol and placebo group at ½, 3 and 6 hours 
postoperatively 
Figure 4.11 Comparison of percentage of patients experiencing dizziness between 
intravenous paracetamol and placebo group at ½, 3 and 6 hours 
postoperatively. 
 
 
  
x 
 
ABSTRAK 
Latarbelakang: Penggunaan intravena paracetamol semasa pembedahan telah 
didapati mengurangkan tahap kesakitan dan penggunaan morfin di kalangan pesakit 
surgikal tertentu. Kami mengkaji kesan intravena paracetamol semasa pembedahan 
terhadap tahap kesakitan selepas pembedahan di kalangan pesakit yang menjalani 
pembedahan ortopedik selepas patah tulang paha, betis atau kaki. Matlamat utama 
kami adalah pengurangan tahap kesakitan and penggunaan morfin sehingga 6 jam 
selepas pembedahan. 
Cara: 62 pesakit yang menjalani pembedahan ortopedik yang melibatkan kepatahan 
tulang paha, betis atau kaki yang memenuhi kriteria telah direkrut di Hospital Sains 
Malaysia dan dirawakkan dalam dua kumpulan. Kumpulan intravena paracetamol (n = 
31) telah menerima intravena paracetamol 1 g (100 ml) ketika tamat pembedahan 
manakala kumpulan placebo (n = 31) telah menerima intravena normal saline (100 ml) 
ketika tamat pembedahan. Kedua-dua kumpulan telah menerima protokol pembiusan 
am yang teratur dan menerima intravena morfin selepas pembedahan menggunakan 
Alat Analgesia Kawalan Pesakit. Tahap kesakitan, penggunaan morfin dan kesan 
sampingan selepas pembedahan direkod pada 30 minit, 3 dan 6 jam selepas 
pembedahan. 
Keputusan: Mean tahap kesakitan adalah lebih rendah dan terbukti berbeza untuk 
kumpulan intravena paracetamol berbanding dengan kumpulan placebo untuk masa 
rehat (mean ± SD = 4.23 ± 1.63 VS 5.42 ± 2.41 at 30 min, p = 0.015; 2.81 ± 1.58 VS 4.19 
± 2.09 at 3 hours, p = 0.005; 2.23 ± 1.20 VS 3.23 ± 1.86 at 6 hours, p = 0.015) and 
moving (mean ± SD = 6.45 ± 1.69 VS 7.26 ± 2.21 at 30 min, p = 0.111; 5.00 ± 1.79 VS 
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6.48 ± 1.86 at 3 hours, p = 0.002; 4.35 ± 1.38 VS 5.35 ± 1.70 at 6 hours, p = 0.014). 
Didapati tiada perbezaan yang ketara dalam penggunaan morfin untuk kumpulan 
intravena paracetamol dan placebo walaupun jumlah terkumpul penggunaan morfin 
adalah lebih rendah untuk kumpulan intravena paracetamol berbanding kumpulan 
placebo (mean ± SD = 14.65 ± 10.12 VS 20.61 ± 14.33, p = 0.063). Kekerapan kesan 
sampingan didapati sama untuk kedua-dua kumpulan. 
Kesimpulan: Kajian ini menunjukkan kebaikkan terhadap penggunaan intravena 
paracetamol sebagai analgesia pelbagai semasa pembedahan untuk pesakit yang 
mengalami kepatahan tulang paha, betis dan kaki. Kami menyarankan penggunaan 
intravena paracetamol dalam analgesia pelbagai untuk merawat kesakitan selepas 
pembedahan. 
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ABSTRACT 
Backgraound: Perioperative intravenous paracetamol has been shown to reduce 
postoperative pain scores and morphine consumption in certain surgical populations. 
We studied the effects of perioperative intravenous paracetamol on postoperative 
pain relief among patients undergoing orthopaedic surgery for lower limb bone 
fractures. Our primary end points were a reduction in postoperative pain score and 
cumulative morphine consumption 6 hours postoperatively 
Methods: 62 patients undergoing orthopaedic surgery involving lower limb bone 
fractures that fulfilled inclusion and exclusion criteria were recruited in Hospital 
Universiti Sains Malaysia and randomized into two groups. The intravenous 
paracetamol group (n = 31) received intravenous paracetamol 1 gram (100 ml) at skin 
closure while the placebo group (n = 31) received intravenous normal saline (100 ml) 
at skin closure. Both groups received a standardized regimen of general anaesthesia 
and were given intravenous morphine postoperatively via a Patient Controlled 
Analgesia Device. Postoperative pain score, cumulative morphine consumption and 
side effects were recorded using a visual analogue scale at 30 minutes, 3 and 6 hours 
postoperatively. 
Results: The mean pain scores were significantly lower in intravenous paracetamol 
group compare to placebo group in resting (mean ± SD = 4.23 ± 1.63 VS 5.42 ± 2.41 at 
30 min, p = 0.015; 2.81 ± 1.58 VS 4.19 ± 2.09 at 3 hours, p = 0.005; 2.23 ± 1.20 VS 3.23 
± 1.86 at 6 hours, p = 0.015) and moving (mean ± SD = 6.45 ± 1.69 VS 7.26 ± 2.21 at 30 
min, p = 0.111; 5.00 ± 1.79 VS 6.48 ± 1.86 at 3 hours, p = 0.002; 4.35 ± 1.38 VS 5.35 ± 
1.70 at 6 hours, p = 0.014). There were no significant different in cumulative morphine 
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consumption between intravenous paracetamol and placebo group despite total 
cumulative morphine consumption for intravenous paracetamol group was lower than 
placebo group (mean ± SD = 14.65 ± 10.12 VS 20.61 ± 14.33, p = 0.063). Incidence of 
side effects was similar between the two groups. 
Conclusion: This study show beneficial effects of perioperative intravenous 
paracetamol as part of multimodal analgesia for patients who have lower limb bone 
fractures going for orthopaedic procedures. We recommended the use of intravenous 
paracetamol as part of multimodal analgesia in treating postoperative pain. 
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CHAPTER 1: INTRODUCTION 
1.1 INTRODUCTION 
Acute postoperative pain is a common and still the major complaint encounter after 
surgery even with current standard of care. In a survey of adults who had undergone 
surgical procedures in the United States, Warfield and colleagues noted that 77% 
reported pain after surgery with 80% of affected individuals experiencing moderate to 
severe pain (Warfield & Kahn, 1995). In another study, in adult who had a variety of 
surgical procedure, Apfelbaum et al. reported approximately 80% of patient 
experiences moderate to severe pain postoperatively (Apfelbaum, Chen, Mehta, & Gan, 
2003). Inadequate pain relief and control is associated with multiple problems. If it is 
not managed effectively, postoperative pain can lead to prolonged rehabilitation, poor 
surgical outcomes and higher rate of medical complication including  increased risk of 
cardiovascular, pulmonary complication and venous thromboembolic disease (Joshi & 
Ogunnaike, 2005; H Kehlet & Holte, 2001). As a consequences all of complications 
lead to delayed recovery and prolonged hospital stay (Morrison et al., 2003). 
Among the different type of surgical procedure, orthopaedic procedure may induce 
more intense pain than other surgical procedures because bone pain is more painful 
than soft tissue injury (Ekman & Koman, 2004). A study by Chung et al. on 
postoperative pain showed that patient, who had underwent orthopaedic surgery had 
highest incidences of severe pain in the post anaesthesia care unit and 24 hour 
postoperatively (Chung, Ritchie, & Su, 1997). For orthopaedic patients, poorly 
controlled postoperative pain may be associated with delay in ambulation, longer 
inpatient hospital stays, and decreased patient satisfaction (Joshi & Ogunnaike, 2005) 
(Morrison et al., 2003). In addition, long-term complications may occur from poorly 
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controlled postoperative pain, such as limited range of motion and chronic pain 
syndrome (Joshi & Ogunnaike, 2005) (Perkins & Kehlet, 2000). 
The usual treatment for postoperative pain in orthopaedic patients has been oral or 
intravenous opioid medication. Unfortunately, these medications are frequently 
associated with multiple adverse reactions, especially nausea and vomiting, pruritus, 
ileus, and constipation. At routine doses in elderly patients and higher doses in other 
postoperative patients, opioid analgesics may be associated with respiratory depression, 
hypotension, dizziness, confusion, and even delirium. These complications usually 
delay patient mobilization with physical therapy, and increase length of hospital stay 
(Pizzi et al., 2012) (Oderda et al., 2007). Thus, opioid mono-therapy is not an adequate 
or appropriate strategy to improve pain management in postoperative patients 
Over the past decade, multimodal analgesia has gained recognition for being an 
effective strategy in managing postoperative pain (Elvir-Lazo & White, 2010; Henrik 
Kehlet & Dahl, 1993). Using different classes of analgesics each with different 
pathways and receptor, multimodal analgesia optimizes analgesic efficacy using lower 
doses of each of respective agents, thus limiting the risk of dose-related adverse events 
(Buvanendran & Kroin, 2009). Many clinician and anaesthesiologist find this approach 
beneficial, particularly when using regimens that allow lower doses of opioids. 
Consequently multimodal analgesia can improved recovery after surgery and ensure 
rehabilitation and reduced hospital length of stay, thus reducing the overall costs. In 
addition to opioids and NSAIDs, multimodal analgesics also include gabapentanoids, 
ketamine, alpha-2 agonists including clonidine and dexmetomidine, and local 
anaesthetics. Intravenous paracetamol is only recently available in our set up. It is 
considered a safe drug and only available for a decade in oral, syrup and suppository 
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form. Now, intravenous paracetamol is considered a fundamental component of the 
multimodal approach to which opioids, NSAIDs and other drugs are added. 
Intravenous paracetamol is only recently available in Malaysia for clinical use. It has 
been use for the management of mild pain, the management of moderate to severe pain 
with adjunctive opioid analgesics and the reduction of fever. Several studies have noted 
its clinical benefit by providing reduced pain scores, opioid consumption, and 
postoperative side effects when used as a postoperative analgesic. 
Several literature review and meta-analysis were done regarding usage of intravenous 
paracetamol intraoperative and postoperative. Marcario and Royal performed a 
literature review of randomized clinical trials of intravenous paracetamol for acute 
postoperative pain. Sixteen articles from nine countries published between 2005 and 
2010 met inclusion criteria and had a total of 1464 patients. In seven of the eight studies 
where intravenous paracetamol was compared with an active comparative medication, 
intravenous paracetamol was found to have similar analgesic outcomes. Three of the 
eight studies also found intravenous paracetamol resulted in significant reduction in 
mean opioid consumption. Twelve of 14 placebo-controlled studies found that 
intravenous paracetamol patients had improved pain relief (Macario & Royal, 2011). 
Another systemic review of clinical trial done by Bright et al. regarding intravenous 
paracetamol reduces postoperative opioid consumption after orthopaedic surgery.  
Eight articles were chosen after review of inclusion and exclusion criteria and analysed. 
Five clinical trials reported that there is significant reduction in opioid consumption in 
the postoperative period. However one study did not find any reduction in opioid 
requirement after spinal surgery in children and adolescents. Studies that reported a 
significant decreased in opioid consumption were done in adult population. Three of 
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them were done in lower limb surgeries, one in a mixed orthopaedic and rest is a spinal 
surgery. Six clinical trials reported a better pain score when paracetamol has been used 
but other three trials denied.  They concluded that postoperative intravenous 
paracetamol is a safe and effective component of multimodal analgesic regimen, and it 
reduces postoperative opioid consumption after orthopaedic surgery (Jebaraj, Maitra, 
Baidya, & Khanna, 2013) 
Most of the clinical trials studied the use of intravenous paracetamol alone compare 
with placebo or active comparator, therefore the use of intravenous paracetamol is 
consider mono-therapy approach for postoperative pain control. A few clinical studies 
used intravenous paracetamol as adjunctive to morphine and use multiple drug 
combination for the treatment of postoperative pain and added intravenous paracetamol 
as a new combination.  
With the concept of multiple modal approaches for postoperative pain management and 
to differentiate from previous study, this study plan to use multi drugs regimes (opioids, 
NSAIDs and local anaesthetics) for pain management and plan to investigate the use of 
additional intravenous paracetamol in reducing postoperative pain and morphine 
consumption postoperatively. To establish this study, orthopaedic surgery involving 
bone fracture for lower limb is choose because this type of surgery we anticipate 
moderate to severe pain postoperatively.  
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1.2 OBEJECTIVE OF THE STUDY 
General Objective: 
The objective of this study was to evaluate the effects of intravenous paracetamol as 
compared to placebo with regards to postoperative pain relief when given 
perioperatively to patients undergo orthopaedic surgery for lower limb bone fractures. 
Specific Objectives: 
1. To evaluate effect of perioperative intravenous paracetamol in reducing 
postoperative visual analogue scale at 30 minutes, 3 hours and 6 hours 
postoperatively 
2. To study the adjunctive effect of intravenous paracetamol in reducing morphine 
consumption over 6 hours postoperatively 
3. To evaluate effect of perioperative intravenous paracetamol on side effects of 
morphine. 
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CHAPTER 2: REVIEW OF LITERATURE 
2.1 PHYSIOLOGY OF ACUTE PAIN 
In 1996 the International Association for the Study of Pain (IASP) defined pain as ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage’(Merskey, 1991). Acute pain is defined 
as pain of recent onset and probable limited duration. It is typically has an identifiable 
cause relationship with injury or disease. Chronic pain commonly persists beyond the 
time of healing of an injury and frequently there may not be any clear identifiable cause 
(Ready & Edwards, 1992). 
Pain is a subjective experience, which cannot be easily measured. It requires 
consciousness. Describing pain as an ‘experience’ separates pain from ‘nociception’. 
Nociception is the neural processes underlying the encoding and processing of a 
noxious stimulus to the brain via a pain pathway (Loeser & Treede, 2008). In addition 
to these sensory effects, the perception and subjective experience of pain is 
multifactorial including signalling systems and modulation from higher centres and will 
be influenced by psychological and environmental factors in every individual. 
The nervous system for nociception that alerts the brain to noxious sensory stimuli is 
separate from the nervous system that informs the brain of innocuous sensory stimuli. 
Nociceptors are unspecialized, free, unmyelinated nerve endings that convert 
(transduce) a variety of stimuli into nerve impulses, which the brain interprets to 
produce the sensation of pain (Steeds, 2013). The nerve cell bodies are located in the 
dorsal root ganglia, or for the trigeminal nerve in the trigeminal ganglia, and they send 
one nerve fiber branch to the periphery and another into the spinal cord or brainstem. 
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The classification of the nociceptor is based on the classification of the nerve fiber of 
which it is the terminal end. There are two types of nerve fibers, Ad fibers and C fiber. 
Ad fibers are myelinated, large diameter 2 -3 microns and conduct at the velocity of 6 – 
30 meter per second. The Aδ-fiber nociceptors are of two types and respond to 
mechanical and mechanothermal stimuli. C fibers are unmyelinated, small-diameter 
less than 2 microns and conduct much slower at the velocity of 0.5 – 2 meters per 
second. The C-fiber nociceptors respond polymodally to thermal, mechanical, and 
chemical stimuli. It is well known that the sensation of pain is made up of two 
categories, an initial fast, sharp pain and a later slow, dull, long lasting pain.  This 
pattern is explained by the difference in the speed of propagation of nerve impulses in 
the two nerve fiber types described above. The neuronal impulses in fast-conducting 
Aδ-fiber nociceptors produce the sensation of the sharp, fast pain, while the slower C-
fiber nociceptors produce the sensation of the delayed, dull pain (Fein, 2012).  
Peripheral activation of the nociceptors (transduction) is modulated by a number of 
chemical substances including neuropeptides and excitatory amino acids, which are 
produced or released when there is cellular damage (Table 2.1) (Butterworth, Markey, 
& Wasnick, 2013). These mediators influence the degree of nerve activity and, hence, 
the intensity of the pain sensation. Repeated stimulation typically causes sensitization 
of peripheral nerve fibers, causing lowering of pain thresholds and spontaneous pain, a 
mechanism that can be experienced as cutaneous hypersensitivity, e.g., in skin areas 
with sunburn. 
In addition, local release of chemicals such substance P causes vasodilation and 
swelling as well as release of histamine from the mast cells, further increasing 
vasodilation. This complex chemical signalling protects the injured area by producing 
behaviours that keep that area away from mechanical or other stimuli. Promotion of 
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healing and protection against infection are aided by the increased blood flow and 
inflammation (the “protective function of pain”). 
 
Table 2.1 Major neurotransmitter mediating and modulating pain 
 
 
Neurotransmitter Receptor Effect on Nociception 
Substance P Neurokinin-1 Excitatory 
Calcitonin gene-related 
peptide 
 Excitatory 
Glutamate NMDA, AMPA, kainite, 
quisqualate 
Excitatory 
Aspartate NMDA, AMPA, kainite, 
quisqualate 
Excitatory 
Adenosine triphosphate (ATP) P1, P2 Excitatory 
Somatostatin  Inhibitory 
Acetylcholine Muscarinic Inhibitory 
Enkephalins µ, δ, κ Inhibitory 
Β-Endorphin µ, δ, κ Inhibitory 
Norepinephrine α2 Inhibitory 
Adenosine A1 Inhibitory 
Serotonin 5-HT1, (5-HT3) Inhibitory 
γ- Aminobutyric acid (GABA) A, B Inhibitory 
Glycine  Inhibitory 
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2.1.1 PAIN PATHWAYS 
Pain is conducted along three neuronal pathways, first order, second order and third 
order neuron that transmit noxious stimuli from the periphery to cerebral cortex 
(Figures 2.1). The majority of first order neuron sends the proximal end of their axon 
into the spinal cord via the dorsal spinal root. Some unmyelinated afferent fibers enter 
the spinal cord via the ventral nerve root. Each neuron has a single axon that bifurcates, 
sending one end to the peripheral tissues it innervates and the other into the dorsal horn 
of the spinal cord. In the dorsal horn, the primary afferent neuron synapses with the 
second order neuron. Pain fibers originating from the head are carried by the trigeminal 
(V), facial (VII), glossopharyngeal (IX) and vagal (X) nerves. 
The major nerve routes (second order neuron) for the transmission of pain and normal 
temperature information from the body and face to the brain are the spinothalamic 
pathway and the trigeminal pathway. In spinothalamic pathway, the nerve fibers from 
the dorsal root ganglia enter the spinal cord through the dorsal root and send branches 
1–2 segments up and down the spinal cord (dorsolateral tract of Lissauer) before 
entering the spinal gray matter, where they make contacts with (innervate) the nerve 
cells in Rexed lamina I (marginal zone) and lamina II (substantia gelatinosa). The Aδ 
fibers innervate the cells in the marginal zone, and the C fibers innervate mainly the 
cells in the substantia gelatinosa layer of the spinal cord. These nerve cells, in turn, 
innervate the cells in the nucleus proprius, another area of the spinal cord gray matter 
(Rexed layers IV, V, and VI), which send nerve fibers across the spinal midline and 
ascend (in the anterolateral or ventrolateral part of the spinal white matter) through the 
medulla and pons and innervate nerve cells located in specific areas of the thalamus. 
This makes up the spinothalamic pathway for the transmission of information on pain  
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Figures 2.1 (A) Pain pathways for upper and lower body (B) Pain pathways for face
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and normal termal stimuli (<45°C). dysfunctions in the thalamic pathways may 
themselves be a source of pain, as is observed in patients after stroke with central pain 
(“thalamic pain”) in the area of paralysis (Butterworth et al., 2013). 
In the trigeminal pathway, noxious stimuli from the face area are transmitted in the 
nerve fibers originating from the nerve cells in the trigeminal ganglion as well as 
cranial nuclei VII, IX, and X. The nerve fibers enter the brainstem and descend to the 
medulla, where they innervate a subdivision of the trigeminal nuclear complex. From 
here the nerve fibers from these cells cross the neural midline and ascend to innervate 
the thalamic nerve cells on the contralateral side. Spontaneous firing of the trigeminal 
nerve ganglion may be the etiology of “trigeminal neuralgia”. 
The area of the thalamus that receives the pain information from the spinal cord and 
trigeminal nuclei is where the third order neuron located. It also the area that receives 
information about normal sensory stimuli such as touch and pressure. From this area, 
nerve fibers are sent to somatosensory area I and II in the postcentral gyrus of the 
parietal cortex and the superior wall of the sylvian fissure. Thus, by having both the 
nociceptive and the normal somatic sensory information converge on the same cortical 
area, information on the location and the intensity of the pain can be processed to 
become a “localized painful feeling.” 
Appreciating the complexity of the pain pathway can contribute to understanding the 
difficulty in assessing the origin of pain in a patient and in providing pain relief, 
especially in chronic pain. 
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2.1.2 MODULATION OF THE PERCEPTION OF PAIN 
It is well known that there is a difference between the objective reality of a painful 
stimulus and the subjective response to it. The dissociation between injury and pain 
implies that there is a mechanism in the body that modulates pain perception. This 
endogenous mechanism of pain modulation is thought to provide the advantage of 
increased survival in all species. There is three important mechanisms have been 
described which is segmental inhibition, the endogenous opioid system, and the 
descending inhibitory nerve system.  
In 1965, Melzack and Wall proposed the “gate theory of pain control,” which has been 
modified subsequently but which in essence remains valid. The theory proposes that the 
transmission of information across the point of contact (synapse) between the Aδ and C 
nerve fibers (which bring noxious information from the periphery) and the cells in the 
dorsal horn of the spinal cord can be diminished or blocked. Hence, the perception of 
the painfulness of the stimulus either is diminished or is not felt at all. The development 
of transcutaneous electrical nerve stimulation (TENS) was the clinical consequence of 
this phenomenon (Kopf & Patel, 2010). 
The transmission of the nerve impulse across the synapse can be described as follows: 
The activation of the large myelinated nerve fibers (Aβ fibers) is associated with the 
low-threshold mechanoreceptors such as touch, which stimulate an inhibitory nerve in 
the spinal cord that inhibits the synaptic transmission. This is a possible explanation of 
why rubbing an injured area reduces the pain sensation. 
Besides the gating of transmission of noxious stimuli, there is another system 
modulates pain perception. Since 4000 BCE, it has been known that opium and its 
derivatives such as morphine, codeine, and heroin are powerful analgesics, and they 
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remain the mainstay of pain relief therapy today. In the 1960s and 1970s, receptors for 
the opium derivatives were found, especially in the nerve cells of the periaqueductal 
gray matter and the ventral medulla, as well as in the spinal cord. This finding implied 
that chemicals must be produced by the nervous systems that are the natural ligands of 
these receptors. Three groups of endogenous compounds (enkephalins, endorphins, and 
dynorphin) have been discovered that bind to the opioid receptors and are referred to as 
the endogenous opioid system. The presence of this system and the descending pain 
modulation system (adrenergic and serotoninergic) provides an explanation for the 
system of internal pain modulation and the subjective variability of pain. 
Nerve activity in descending nerves from certain brainstem areas (periaqueductal gray 
matter, rostral medulla) can control the ascent of nociceptive information to the brain. 
Serotonin and norepinephrine are the main transmitters of this pathway, which can 
therefore be modulated pharmacologically. Selective serotonin reuptake inhibitors 
(SSRIs) and tricyclic antidepressants (e.g., amitriptyline) may therefore have analgesic 
properties. 
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2.2 CONCEPT OF MULTIMODAL ANALGESIA 
The concept of multimodal analgesia was introduced long time ago as a technique to 
improve analgesia and reduce the incidence of opioid related adverse events. What is 
multimodal analgesia?  Multimodal analgesia is achieved by combining different 
analgesics that act by different mechanisms and at different sites in the nervous system 
(e.g., opioids, NSAIDs, and local anaesthetics), resulting in additive or synergistic 
analgesia (Henrik Kehlet & Dahl, 1993) (Figure 2.2). 
 
Figure 2.2 Types of Analgesics and Their Site of Action. 
The aim of this strategy is to achieve sufficient analgesia, reduce the doses of individual 
drugs and lower the incidence of adverse drug effects. In a study by Christine et. al, 
they study the combination of drugs, opioids (mepiridine), NSAID (ketorolac) and local 
anaesthesia in ambulatory laparoscopic cholecystectomy. They conclude that, the 
concomitant use of opioid, NSAID and local anaesthesia to be highly effective in 
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patients, resulting in faster recovery and discharge (Michaloliakou, Chung, & Sharma, 
1996).  A lower incidence of adverse effects and improved analgesia also has been 
demonstrated with multimodal analgesia techniques, which may provide for shorter 
hospitalization times, improved recovery and function and possibly decreased 
healthcare costs (Buvanendran et al., 2003). 
It has been suggested that multimodal analgesia is a rational approach to pain 
management and is more effective (Carpenter, 1997). Animal studies also demonstrate 
the synergistic effect between NSAIDs and opioids, and certain other analgesics in 
clinical pain states (Malmberg & Yaksh, 1993). Therefore, multimodal analgesia is 
currently recommended for effective postoperative pain control.  
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2.2.1 OPIOIDS 
Opioid are the most effective analgesics, especially for moderate to severe 
postoperative pain (Claxton, McGuire, Chung, & Cruise, 1997). Their effects are 
mediated by opioid receptors in the central nervous system that attenuate pain related 
signal. Peripheral opioid receptors also provide analgesic effects (Stein, 1993). The 
potency of individual opioids correlates with their affinity for their respective receptors 
(Stahl, Van Bever, Janssen, & Simon, 1977). The side effect profile of opioids which is 
nausea, vomiting, sedation, ileus, constipation and respiratory depression should be 
considered when using it as a sole analgesic for postoperative pain. In order to reduce 
the dose of opioids, other non-opioids analgesics should be considered.  
There are many types and route for opioids is available. Morphine is common opioids 
used for postoperative pain relieved especially for moderate to severe pain. The 
common route for morphine in postoperative setting includes intravenous by small 
boluses titration or via patients controlled analgesia machine (PCA), intramuscular, 
subcutaneous and neuroaxial. PCA morphine is still superior in the management of 
postoperative pain especially in ward (Walder, Schafer, Henzi, & Tramer, 2001). And it 
became a standard of care in procedures where moderate to severe postoperative pain is 
expected. Another route that are commonly use is neuroaxial morphine. It provides 
excellent postoperative analgesia for up to 24 hours. However, in those patient received 
opioids especially morphine, delayed respiratory depression remains a concern and 
these patients need to be monitored closely postoperatively. Alternatively, fentanyl, a 
short acting opioids are appropriate than longer acting opioids for PCA and neuroaxial 
(Gross et al., 2006). Most of the clinical trials of analgesics use opioids as comparator 
and end objective of study especially morphine. 
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2.2.2 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have proved to be valuable in the 
management of postoperative pain because of their opioid sparing action and anti-
inflammatory effects (Cashman, 1996). We know that Prostaglandins, including PGE2, 
are responsible for reducing the pain threshold at the site of injury, resulting in central 
sensitization and a lower pain threshold in the surrounding uninjured tissue. The 
primary site of action of NSAIDs is believed to be in the periphery though recent 
research indicates that central inhibition of cyclooxygenase-2 (COX-2) may also play 
an important role in modulating nociception (Buvanendran et al., 2006). NSAIDs 
inhibit the synthesis of prostaglandins both in the spinal cord and at the periphery, thus 
diminishing the hyperalgesic state after surgical trauma.    
Oral NSAIDs have long been used for treating postoperative pain. However it only 
used in those patients whose can tolerated orally. Since parenteral preparations of 
NSAIDs have become available, these drugs have been more widely used in the 
management of acute perioperative pain.    
Early reports suggested that parenteral NSAIDs possessed analgesic properties 
comparable to the traditional opioid analgesics (Yee, Koshiver, Allbon, & Brown, 
1986) without opioid related side effects (Ding & White, 1992). Compared with the 
partial opioid agonist tramadol, diclofenac produced better postoperative pain relief 
with fewer side effects after cardiac surgery (Immer et al., 2003). When administered as 
an adjuvant during outpatient anaesthesia, ketorolac was associated with improved 
postoperative analgesia and patient comfort compared with fentanyl and dezocine 
(Ding & White, 1992). Other investigators reported that ketorolac provided 
postoperative pain relief similar to that of fentanyl but was associated with less nausea 
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and somnolence, as well as an early return to of bowel function (Wong et al., 1993). In 
most studies, use of ketorolac has been associated with less frequent incidence of 
postoperative nausea vomiting then the opioid analgesics. As a result, patients tolerate 
oral fluids and are fit for discharge earlier than those receiving only opioid analgesics 
during perioperative period.  
Oral and rectal administration of NSAIDs is also effective and less costly in the 
management of postoperative pain (Forse, El-Beheiry, Butler, & Pace, 1996). For 
example, when oral naproxen was administered before laparoscopic surgery, 
postoperative pain scores, opioid requirements and time to discharge were significantly 
reduced (Rosenblum, Weller, Conard, Falvey, & Gross, 1991) . 
 Despite the obvious benefits of using NSAIDs in the postoperative period, as with any 
mixed COX-1/COX-2 inhibitor, the primary concern would be the increased 
postoperative bleeding that has been documented for NSAIDs because of their COX-1 
component (Marret, Flahault, Samama, & Bonnet, 2003). 
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2.2.3 COX-2 SELECTIVE INHIBITOR 
COX-2-selective inhibitors have the advantage over NSAIDs in the perioperative 
setting of not increasing the risk of bleeding. Multiple clinical studies in surgical 
patients evaluated the use of celecoxib, rofecoxib and valdecoxib as preventive 
analgesics. In a study comparing celecoxib versus placebo done in patients undergoing 
total knee arthroplasty under spinal anaesthesia show lower pain scores and morphine 
consumption over the first 48h. Celecoxib also increased knee range of motion over the 
first 3 postoperative days. Incidences of postoperative nausea and vomiting (PONV) 
did not differ by group. As expected with a COX-2-selective inhibitor, there were no 
differences in intraoperative or postoperative blood loss between groups (Huang et al., 
2008). 
Rofecoxib is a COX-2-selective inhibitor that is no longer used due to adverse 
cardiovascular events. However, clinical trials with acute use of rofecoxib during joint 
replacement surgery reveal mechanisms by which COX-2 inhibition can reduce 
postoperative pain. Perioperative use of rofecoxib reduced opioid consumption, pain, 
vomiting, and sleep disturbance, with improved knee range of motion compared with 
that of placebo, after total knee arthroplasty (Buvanendran et al., 2003).  
Most of the COX-2 selective inhibitor is available only in an oral formulation. A 
parenteral form of a new COX-2 selective inhibitor which is parecoxib is currently 
available. Parecoxib is a prodrug which is rapidly converted to valdecoxib. It has been 
shown to be effective as an analgesic post gynaecological surgery in a 24 hour study 
with ketorolac as comparators (Barton et al., 2002). Postoperative administration of 
parecoxib resulted in significant opioid sparing effects, reduced adverse effects and 
improved quality of recovery and patient satisfaction with postoperative pain 
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management (Malan Jr et al., 2003). In a 7 day study of parecoxib and ketorolac in 
elderly patients parecoxib was associated with similar GI effects to placebo, with 
significantly fewer gastric and duodenal erosions and ulcers than ketorolac (Hubbard et 
al., 2000). 
In view of benefits of NSAIDs and COX-2 selective inhibitor in postoperative pain 
management, recent practice guidelines for acute pain management in the perioperative 
setting specifically state ‘unless contraindicated, all patients should receive around-the-
clock regimen of NSAIDs, COX-2 inhibitors, or acetaminophen’ (Management, 2004). 
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2.2.4 NMDA ANTAGONISTS 
With the discovery of the N-methyl-D-aspartate (NMDA) receptor and its links to 
nociceptive pain transmission and central sensitization, there has been renewed interest 
in utilizing non-competitive NMDA receptor antagonists, such as ketamine, as potential 
anti-hyperalgesic agents. Ketamine has been a well-known general anaesthetic and 
analgesic for the past 3 decades. Although high doses of ketamine have been implicated 
in causing psychomimetic effects (excessive sedation, cognitive dysfunction, 
hallucinations, nightmares), sub-anaesthetic or low doses of ketamine have 
demonstrated significant analgesic efficacy without these side effects. Low-dose 
ketamine has not been associated with adverse pharmacological effects on respiration, 
cardiovascular function, nausea, vomiting, urinary retention, and constipation or 
postoperative ileus.  
There is evidence that low-dose ketamine may play an important role in postoperative 
pain management when used as an adjunct to opioids, local anaesthetics, and other 
analgesic agents (Schmid, Sandler, & Katz, 1999; Subramaniam, Subramaniam, & 
Steinbrook, 2004). A recent review of 70 studies with 4701 patients, confirmed that 
perioperative opioid consumption was lower, postoperative nausea and vomiting was 
decreased and that ketamine was especially useful in very painful procedures such as 
thoracic and major orthopaedic surgery. The analgesic effect of ketamine was 
independent of the type of intraoperative opioid, timing of ketamine administration and 
ketamine dose (Laskowski, Stirling, McKay, & Lim, 2011). 
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2.2.5 ALPHA-2 AGONIST 
Alpha-2 adrenergic activation represents an intrinsic pain control network of the central 
nervous system. The alpha-2 adrenergic receptor has high density in the substantia 
gelatinosa of the dorsal horn in humans and that is believed to be the primary site of 
action by which alpha-2 adrenergic agonists can reduce pain. Clonidine and the more 
selective dexmedetomidine have opioid sparing, sedative and analgesics properties 
(Smith, 2011). Unfortunately the analgesic doses of these drugs cause significant side 
effects in the form of sedation, hypotension and bradycardia. They are also very long 
acting and can cause delay awakening after general anaesthesia.  
Due to the many side effects of systemic clonidine administration, the spinal route is 
preferred. In a study compare epidural clonidine versus placebo for spinal surgery 
under general anaesthesia, shown PCA morphine use, pain score and PONV incidence 
was less in the clonidine group than placebo (Farmery & Wilson-MacDonald, 2009). In 
a study of patients undergoing abdominal total hysterectomy under general anaesthesia 
were compare between morphine alone or dexmedetomidine plus morphine for 
postoperative analgesia over 24 h. Patients with dexmedetomidine and morphine 
required less morphine (23mg) than the morphine alone group (33 mg) over the 0–24 h 
postoperative period. Postoperative pain scores at rest or with movement and the 
incidence of nausea during the 4– 24 h period were lower in the dexmedetomidine and 
morphine group. There was lower blood pressure and heart rate in the 
dexmedetomidine and morphine group, but the decrease was small (Lin et al., 2009). 
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2.2.6 GABAPENTANOIDS 
Pregabalin and gabapentin used extensively in the treatment of chronic neuropathic 
pain and seizure, reduce postoperative pain if given pre and postoperatively. 
Preemptive pregabalin decreases postoperative pain scores, opioid consumption as well 
as opioid related adverse effects. However postoperative sedation is increased (Peng, 
Wijeysundera, & Li, 2007). Pregabalin and gabapentin bind to the a2d subunit of 
voltage-gated calcium channels in the spinal cord and brain (Bian et al., 2006). Earlier 
clinical trials with gabapentin for early postsurgical pain have recently been reviewed 
(Gilron, 2007). In patients undergoing laparoscopic cholecystectomy were randomized 
to receive pregabalin 150mg or placebo orally 1 h before surgery. Opioid consumption 
and pain score were less in the pregabalin group. However PONV incidence, or 
sedation, did not differ between the two groups (Agarwal et al., 2008).   
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2.2.7 LOCAL ANAESTHETICS 
Local anaesthetics can be administered for perioperative pain management via different 
routes either by peripheral nerve blocks or wound infiltration. Peripheral nerve blocks 
techniques are simple, safe and highly effective approaches to providing perioperative 
analgesia. The use of long acting local anaesthetics for neural blockage techniques 
involving the upper and lower extremities can facilitate an early discharge. Extending 
peripheral nerve blocks using disposable catheter systems to provide continuous 
perineural blockage has been shown to improve recovery after both upper and lower 
extremities (White, Issioui, Skrivanek, Early, & Wakefield, 2003).  
Infiltrating local anaesthetics into the skin and subcutaneous tissue prior to making an 
incision may be the simplest approach to analgesia. It is a safe procedure with few side 
effects and low risk for toxicity. When administered before surgery, this simple 
technique can also decrease anaesthetic and analgesic requirements during surgery, as 
well as reduce the need for opioid analgesics postoperatively. In patients undergoing 
total abdominal hysterectomy under general anaesthesia, bilateral block of the 
abdominal wall with ropivacaine shown less morphine use over the 48 h period after 
surgery compare to placebo group. Pain scores at rest and with movement were reduced 
in the ropivacaine group. The incidence of PONV did not differ between groups, but 
the incidence of sedation was reduced in the ropivacaine group (Carney, McDonnell, 
Ochana, Bhinder, & Laffey, 2008).  
  
